Electronic-instrument giant Danaher (DHR) said Monday it’s buying Swiss dental-equipment maker Nobel Biocare for $2.2 billion in cash, ending weeks of rumors. The highly diversified Danaher already has a business in high-tech dental gear, which the company believes will work nicely with Nobel’s specialty in reconstructive implants. “Bringing Nobel Biocare’s deep expertise in implant dentistry, digital prosthetics and software together with our
High-tech instrument maker Danaher (DHR) reported a soft Q2 and guidance early Thursday, sending its stock tumbling nearly 5% in morning trading on the stock market today. Earnings per share rose 9% over the year-earlier quarter to 95 cents, including 2 cents from an after-tax gain from the sale of securities. Analysts’ consensus called for 94 cents. Sales rose 5% to $4.96 billion, vs. consensus of $4.97 billion. The company guided Q3 EPS of 86 to
Scientific instrument maker Danaher (DHR) was down 1.5% in heavy volume in morning trading on the stock market today after it announced a new CEO and guided Q2 a bit below consensus. Late Wednesday, Danaher released Q1 earnings and announced that CEO Lawrence Culp will retire in March 2015 after 14 years on the job. He will be replaced by Thomas Joyce, head of the company’s life-science and diagnostics business. On a conference call with analysts